Vol 3, No 3 (2012)
Review paper
Published online: 2012-10-11

open access

Page views 766
Article views/downloads 1650
Get Citation

Connect on Social Media

Connect on Social Media

Plasma cell myeloma — management recommendation of the Institute of Hematology and Transfusion Medicine

Jarosław Czyż, Krzysztof Warzocha
Hematologia 2012;3(3):255-266.

Abstract

In the recent years significant progress has been made in the diagnosis and treatment of
plasma cell myeloma. Implementation of new generation tests such as serum free light chain
assessment as well as novel drug agents, like proteosome inhibitors and immunomodulators
has significantly increased the number of diagnostic and therapeutic options available in
specialized haematology centres. On the other hand, the cost of treatment procedures has
dramatically increased therefore administrative restrictions in the access to novel drugs has
become a necessity. As a response the National Health Found produced, among others,
therapeutic programme regulating an access to the treatment with bortezomibe. To optimize
the utilization of available resources, the Institute of Hematology and Transfusion Medicine
has introduced internal recommendations regarding procedures related to diagnosis and treatment of plasma cell myeloma. These recommendations are based on the guidelines issued
by the British Committee for Standards in Haematology and the Royal College of Radiologists.
Some modifications have been introduced based on more recent publications.

Article available in PDF format

View PDF (Polish) Download PDF file



Hematology in Clinical Practice